Cardiff Oncology Q2 net loss narrows to $9.2 million from $13.9 million
Cardiff Oncology reported a second-quarter 2026 net loss of $9.2 million, or $0.14 per share, down from $13.9 million, or $0.21 per share, a year earlier, as research and development spending fell. Royalty revenue slipped to $104,000 from $121,000, and cash, cash equivalents and short-term investments were $34.5 million at June 30, 2026, before a $10 million registered direct offering completed after quarter end. The company says its cash resources fund operations into the third quarter of 2027, and it plans to start a Phase 3 trial in the first quarter of 2027 subject to securing additional financing.
Key points
- Q2 2026 net loss was $9.2 million ($0.14 per share) versus $13.9 million ($0.21 per share) in Q2 2025.
- Royalty revenue was $104,000 versus $121,000; total operating expenses were $9.7 million versus $14.9 million.
- Cash, cash equivalents and short-term investments were $34.5 million at June 30, 2026, excluding the $10 million offering completed after quarter end.
- Cash resources are expected to fund operations into the third quarter of 2027; Phase 3 start planned for Q1 2027, subject to additional financing.
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.